Patents by Inventor David Andrew Griffith

David Andrew Griffith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dipeptide derivatives
    Publication number: 20040009984
    Abstract: This invention is directed to compounds of the formula 1
    Type: Application
    Filed: February 21, 2003
    Publication date: January 15, 2004
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Dipeptide derivatives
    Publication number: 20040006063
    Abstract: This invention is directed to compounds of the formula 1
    Type: Application
    Filed: February 21, 2003
    Publication date: January 8, 2004
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Dipeptide derivatives
    Publication number: 20030216399
    Abstract: This invention is directed to compounds of the formula 1
    Type: Application
    Filed: February 21, 2003
    Publication date: November 20, 2003
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines
    Publication number: 20030069246
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: February 25, 2002
    Publication date: April 10, 2003
    Applicant: Neurogen Corporation
    Inventors: James W. Darrow, Stephane J. De Lombaert, Charles A. Blum, Jennifer N. Tran, Mark A. Giangiordano, David Andrew Griffith, Philip Albert Carpino
  • Dipeptide derivatives
    Patent number: 6525047
    Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: February 25, 2003
    Assignee: Pfizer Inc.
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
    Patent number: 6476038
    Abstract: Disclosed are compounds of the formula: where R1, R2, R3, R4, R5, R6, and X are defined herein. These compounds are selective modulators of NPY1 receptors. These compounds are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of NPY1 receptors and as standards in assays for NPY1 receptor binding. Methods of using the compounds in receptor localization studies are given.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: November 5, 2002
    Assignees: Neurogen Corporation, Pfizer Inc.
    Inventors: James W. Darrow, Stéphane De Lombaert, Charles Blum, Jennifer Tran, Mark Giangiordano, David Andrew Griffith, Philip Albert Carpino
  • Dipeptide derivatives
    Patent number: 6432945
    Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: August 13, 2002
    Assignee: Pfizer Inc.
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Dipeptide derivatives
    Patent number: 6433171
    Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or fraility, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: August 13, 2002
    Assignee: Pfizer Inc.
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Dipeptide derivatives
    Patent number: 6429313
    Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: August 6, 2002
    Assignee: Pfizer Inc.
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Dipeptide derivatives
    Publication number: 20020065284
    Abstract: This invention is directed to compounds of the formula 1
    Type: Application
    Filed: March 30, 2001
    Publication date: May 30, 2002
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines
    Patent number: 6372743
    Abstract: Disclosed are compounds of the formula: where R1, R2, R3, R4, R5, R6, and X are defined herein. These compounds are selective modulators of NPY1 receptors. These compounds are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of NPY1 receptors and as standards in assays for NPY1 receptor binding. Methods of using the compounds in receptor localization studies are given.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: April 16, 2002
    Assignees: Neurogen Corporation, Pfizer Inc.
    Inventors: James W. Darrow, Stephane De Lombaert, Charles Blum, Jennifer Tran, Mark Giangiordano, David Andrew Griffith, Philip Albert Carpino
  • Dipeptide derivatives
    Publication number: 20020042415
    Abstract: This invention is directed to compounds of the formula 1
    Type: Application
    Filed: March 30, 2001
    Publication date: April 11, 2002
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Dipeptide derivatives
    Publication number: 20020002165
    Abstract: This invention is directed to compounds of the formula 1
    Type: Application
    Filed: March 30, 2001
    Publication date: January 3, 2002
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Dipeptide derivatives
    Publication number: 20010041703
    Abstract: This invention is directed to compounds of the formula 1
    Type: Application
    Filed: March 30, 2001
    Publication date: November 15, 2001
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Dipeptide derivatives as growth hormone secretagogues
    Patent number: 6251902
    Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.
    Type: Grant
    Filed: September 8, 1999
    Date of Patent: June 26, 2001
    Assignee: Pfizer Inc.
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker